Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia
BACKGROUND: Magnesium sulphate remains the drug of choice for both prevention and treatment of women with eclampsia. Regimens for administration of this drug have evolved over the years, but have not yet been formally evaluated.
OBJECTIVES: To assess the comparative effects of alternative regimens for the administration of magnesium sulphate when used for the care of women with pre-eclampsia or eclampsia, or both.
SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (June 2010).
SELECTION CRITERIA: Randomised trials comparing different regimens for administration of magnesium sulphate used for the care of women with pre-eclampsia or eclampsia, or both.
DATA COLLECTION AND ANALYSIS: All four review authors assessed trial quality and extracted data independently.
MAIN RESULTS: We identified 17 studies of which six (866 women) met the inclusion criteria: two trials (451 women) compared regimens for women with eclampsia and four (415 women) for women with pre-eclampsia.Treatment of eclampsia: one trial compared loading dose alone with loading dose plus maintenance therapy for 24 hours (401 women). There was no clear difference between the groups in the risk ratio (RR) of recurrence of convulsions (RR 1.13, 95% confidence interval (CI) 0.42 to 3.05) or stillbirth (RR 1.13, 95% CI 0.66 to 1.92), and the CIs are wide. One trial compared a low dose regimen with a standard dose regimen over 24 hours (50 women). This study was too small for any reliable conclusions about the comparative effects.Prevention of eclampsia: one trial compared intravenous with intramuscular maintenance regimen for 24 hours (17 women). This trial was too small for any reliable conclusions. Three trials compared short maintenance regimens postpartum with continuing for 24 hours after the birth (398 women), even taken together these trials were too small for any reliable conclusions.
AUTHORS' CONCLUSIONS: Although strong evidence supports the use of magnesium sulphate for prevention and treatment of eclampsia, trials comparing alternative treatment regimens are too small for reliable conclusions.
| Errataetall: |
UpdateIn: Cochrane Database Syst Rev. 2023 Oct 10;10:CD007388. - PMID 37815037 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
2010 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2010 |
|---|---|
| Enthalten in: |
The Cochrane database of systematic reviews - (2010), 8 vom: 04. Aug., Seite CD007388 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Duley, Lelia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7487-88-9 |
|---|
| Anmerkungen: |
Date Completed 25.08.2010 Date Revised 10.04.2024 published: Electronic UpdateIn: Cochrane Database Syst Rev. 2023 Oct 10;10:CD007388. - PMID 37815037 Citation Status MEDLINE |
|---|
| doi: |
10.1002/14651858.CD007388.pub2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM200102389 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM200102389 | ||
| 003 | DE-627 | ||
| 005 | 20240410231935.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/14651858.CD007388.pub2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM200102389 | ||
| 035 | |a (NLM)20687086 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Duley, Lelia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.08.2010 | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Cochrane Database Syst Rev. 2023 Oct 10;10:CD007388. - PMID 37815037 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Magnesium sulphate remains the drug of choice for both prevention and treatment of women with eclampsia. Regimens for administration of this drug have evolved over the years, but have not yet been formally evaluated | ||
| 520 | |a OBJECTIVES: To assess the comparative effects of alternative regimens for the administration of magnesium sulphate when used for the care of women with pre-eclampsia or eclampsia, or both | ||
| 520 | |a SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (June 2010) | ||
| 520 | |a SELECTION CRITERIA: Randomised trials comparing different regimens for administration of magnesium sulphate used for the care of women with pre-eclampsia or eclampsia, or both | ||
| 520 | |a DATA COLLECTION AND ANALYSIS: All four review authors assessed trial quality and extracted data independently | ||
| 520 | |a MAIN RESULTS: We identified 17 studies of which six (866 women) met the inclusion criteria: two trials (451 women) compared regimens for women with eclampsia and four (415 women) for women with pre-eclampsia.Treatment of eclampsia: one trial compared loading dose alone with loading dose plus maintenance therapy for 24 hours (401 women). There was no clear difference between the groups in the risk ratio (RR) of recurrence of convulsions (RR 1.13, 95% confidence interval (CI) 0.42 to 3.05) or stillbirth (RR 1.13, 95% CI 0.66 to 1.92), and the CIs are wide. One trial compared a low dose regimen with a standard dose regimen over 24 hours (50 women). This study was too small for any reliable conclusions about the comparative effects.Prevention of eclampsia: one trial compared intravenous with intramuscular maintenance regimen for 24 hours (17 women). This trial was too small for any reliable conclusions. Three trials compared short maintenance regimens postpartum with continuing for 24 hours after the birth (398 women), even taken together these trials were too small for any reliable conclusions | ||
| 520 | |a AUTHORS' CONCLUSIONS: Although strong evidence supports the use of magnesium sulphate for prevention and treatment of eclampsia, trials comparing alternative treatment regimens are too small for reliable conclusions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Systematic Review | |
| 650 | 7 | |a Anticonvulsants |2 NLM | |
| 650 | 7 | |a Calcium Channel Blockers |2 NLM | |
| 650 | 7 | |a Magnesium Sulfate |2 NLM | |
| 650 | 7 | |a 7487-88-9 |2 NLM | |
| 700 | 1 | |a Matar, Hosam E |e verfasserin |4 aut | |
| 700 | 1 | |a Almerie, Muhammad Qutayba |e verfasserin |4 aut | |
| 700 | 1 | |a Hall, David R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Cochrane database of systematic reviews |d 1996 |g (2010), 8 vom: 04. Aug., Seite CD007388 |w (DE-627)NLM107221543 |x 1469-493X |7 nnns |
| 773 | 1 | 8 | |g year:2010 |g number:8 |g day:04 |g month:08 |g pages:CD007388 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/14651858.CD007388.pub2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2010 |e 8 |b 04 |c 08 |h CD007388 | ||